Hagihara Atsushi, Teranishi Yuga, Kawamura Etsushi, Fujii Hideki, Iwai Shuji, Morikawa Hiroyasu, Enomoto Masaru, Tamori Akihiro, Kawada Norifumi
Department of Hepatology, Osaka City University Hospital, Japan.
Intern Med. 2013;52(14):1589-92. doi: 10.2169/internalmedicine.52.9340. Epub 2013 Jul 15.
The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. We herein present the case of a 65-year-old man with multiple lung metastases of hepatocellular carcinoma. Because the patient had liver cirrhosis of Child-Pugh B accompanied by pancytopenia, sorafenib administration was initiated at a dose of 400 mg daily. Although he received sorafenib for only 21 days, the patient exhibited complete regression of the tumors. There was no clinical evidence of recurrence without the administration of anticancer treatment. It is unique that short-term sorafenib treatment achieved a complete response.
晚期肝细胞癌患者服用索拉非尼后的缓解率和总生存率并不理想。我们在此报告一例65岁男性肝细胞癌伴多发肺转移的病例。由于该患者患有Child-Pugh B级肝硬化并伴有全血细胞减少，索拉非尼以每日400毫克的剂量开始服用。尽管他仅服用索拉非尼21天，但肿瘤完全消退。在未进行抗癌治疗的情况下，没有复发的临床证据。短期索拉非尼治疗取得完全缓解是很独特的。
